CPRX250117C17500
- 2.50
- -1.30-34.21%
Catalyst Pharmaceuticals Newsroom
Catalyst Pharmaceuticals Management to Meet With Truist
Express News | Catalyst Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $30 From $31
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) Have Seen Incredible Returns of 477% Over the Past Five Years
Catalyst Pharmaceuticals Inc. Stock Rises Tuesday, Still Underperforms Market
Why Catalyst Pharmaceutical (CPRX) Is a Top Momentum Stock for the Long-Term
Is Catalysts Pharmaceuticals, Inc. (CPRX) the Best Performing Biotech Stock in 2024?
BofA Securities Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating
PepGen Stock Craters 35% on FDA Clinical Hold
Catalyst Pharmaceuticals CEO Richard J. Daly to Present at 43rd Annual J.P. Morgan Healthcare Conference
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
We Ran A Stock Scan For Earnings Growth And Catalyst Pharmaceuticals (NASDAQ:CPRX) Passed With Ease
Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500 List
Insider Sale: Director at $CPRX (CPRX) Sells 72,500 Shares
Catalyst Pharmaceuticals(CPRX.US) Director Sells US$3.63 Million in Common Stock
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
Stephens Initiates Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Announces Target Price $35
Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals With Overweight Rating, Announces Price Target of $35
Catalyst Pharmaceuticals(CPRX.US) Director Sells US$3.1 Million in Common Stock
Sentiment Still Eluding Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)
Catalyst Pharmaceuticals(CPRX.US) Director Sells US$11.51 Million in Common Stock